Much anticipated knockoff versions of costly biotech medicines are facing delays and obstacles that could cost patients and health systems billions in missed savings.
Several high-profile projects to create so-called biosimilar drugs have faltered in recent months. Merck & Co. dissolved a dedicated biosimilar unit last year and in December retreated from a plan to copy arthritis treatment Enbrel after maker Amgen Inc. gained a new patent. Last fall, Samsung Electronics Co.'s biosimilar unit suspended trials for a version of the cancer drug Rituxan, and generic-drug maker Teva Pharmaceutical Industries Ltd. halted its own Rituxan push.
Read the full story: http://on.wsj.com/XCgjT8
Source: The Wall Street Journal
Bridging the Vaccination Gap: Insights on Global Immunization Challenges
July 30th 2024On this episode of Managed Care Cast, we speak with Jeffery A. Goad, PharmD, MPH, 2024-2025 president of the National Foundation for Infectious Diseases, on the recent report from the World Health Organization and UNICEF on public immunization rates, with national and global health implications.
Listen
Despite Record ACA Enrollment, Report Reveals Underinsured Americans Are in Crisis
November 21st 2024Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access to and affordability of health care.
Read More
Double Trouble: High-Deductible Plans Raise Maternity Care Costs Across 2 Calendar Years
June 27th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the June 2024 issue of The American Journal of Managed Care® about how annual high-deductible insurance plans increase maternity care costs when pregnancies cross 2 calendar years.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Support and Skepticism Emerge as Reactions to Robert F. Kennedy Jr’s HHS Nomination
November 15th 2024In the hours after President-elect Donald J. Trump tapped Robert F. Kennedy Jr to lead HHS, reactions came swiftly to the controversial pick who would have a large influence to shake up public health.
Read More